Stockscreener 앱 받기
21.94
3.94%
-0.90
전일 마감가:
$22.84
열려 있는:
$22.6
하루 거래량:
398.60K
Relative Volume:
0.91
시가총액:
$813.88M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.96%
1개월 성능:
-0.23%
6개월 성능:
+38.86%
1년 성능:
+8.88%
1일 변동 폭
$21.85
$22.86
1주일 범위
$21.85
$24.33
52주 변동 폭
$10.01
$26.04
Ceribell Inc Stock (CBLL) Company Profile
명칭
Ceribell Inc
전화
(800) 436-0826
주소
360 N. PASTORIA AVENUE, SUNNYVALE
CBLL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
21.94 | 847.27M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-06-24 | 개시 | BTIG Research | Buy |
| 2025-04-04 | 개시 | Ladenburg Thalmann | Buy |
| 2024-11-05 | 개시 | BofA Securities | Buy |
| 2024-11-05 | 개시 | Canaccord Genuity | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
모두보기
Ceribell Inc 주식(CBLL)의 최신 뉴스
FDA clearances: Siemens Healthineers, Medtronic, CeriBell - Modern Healthcare News
Risk Hedge: Does CeriBell Inc stock reflect fundamentalsJuly 2025 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion - Yahoo Finance
Growth Value: Does CeriBell Inc have consistent dividend growthAnalyst Downgrade & Real-Time Market Trend Scan - baoquankhu1.vn
Protara, Ceribell rise on FDA breakthrough designations - MSN
CBLL: FDA-cleared AI neuromonitoring expands to pediatrics and delirium, driving growth and efficiency - TradingView — Track All Markets
CBLL: 2026 growth will accelerate with new FDA clearances, VA expansion, and pediatric launches - TradingView — Track All Markets
Ceribell sues Natus Medical for patent infringement - MSN
CeriBell, Inc. (NASDAQ:CBLL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Ceribell shares advance after FDA grants breakthrough device status - MSN
CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon - simplywall.st
Is CeriBell Inc. stock a buy on dips2025 Top Decliners & Long-Term Safe Return Strategies - Улправда
Is CeriBell Inc. stock attractive for retirement portfoliosOptions Play & AI Driven Price Predictions - ulpravda.ru
Will CeriBell Inc. stock rally after Fed decisions2025 Key Highlights & Reliable Intraday Trade Plans - ulpravda.ru
Aug Technicals: Why CeriBell Inc. stock could outperform in 2025Portfolio Risk Summary & High Return Trade Opportunity Guides - ulpravda.ru
CeriBell (NASDAQ:CBLL) VP David Foehr Sells 5,556 Shares - MarketBeat
Ceribell’s Foehr sells $125k in shares after option exercise By Investing.com - Investing.com Nigeria
Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell CEO Chao Xingjuan sells $1.68 million in shares By Investing.com - Investing.com South Africa
Ceribell CEO Chao Xingjuan sells $1.68 million in shares - Investing.com
Pittsburgh Post-GazetteCeriBell, Inc.Common Stock (Nasdaq:CBLL) Detailed Stock Data - FinancialContent
Will CeriBell Inc. stock benefit from infrastructure spendingFootwear buying guidance for recovery days and low impact training focuses on balanced cushioning and support, making it a solid option for daily use. - ulpravda.ru
Ceribell director resigns to pursue other professional ventures - MSN
Ceribell Gets FDA Breakthrough Device Status - Medical Device and Diagnostic industry
Ceribell’s AI Stroke Detection Tool Gains FDA Breakthrough Status - Zenopa
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection - Yahoo Finance
FDA grants breakthrough designation for Ceribell’s stroke detection monitor By Investing.com - Investing.com Nigeria
Ceribell receives FDA breakthrough device designation for LVO SD monitor - TipRanks
CeriBell (NASDAQ:CBLL) Hits New 12-Month HighHere's Why - MarketBeat
Ceribell Wins FDA Breakthrough Status for LVO Stroke Tool - TipRanks
Ceribell, Inc. Receives FDA Breakthrough Device Designation for LVO Stroke Solution - TradingView — Track All Markets
Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha
Ceribell receives FDA breakthrough device designation for LVO stroke detection - marketscreener.com
Ceribell’s LVO Stroke Detection Monitor Wins FDA Breakthrough Nod - Medical Product Outsourcing
CeriBell stock climbs after FDA Breakthrough Device Designation By Investing.com - Investing.com Nigeria
FDA grants breakthrough designation for Ceribell’s stroke detection monitor - Investing.com India
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution - marketscreener.com
Ceribell director Lucian Iancovici resigns from board and committees By Investing.com - Investing.com Nigeria
Ceribell director Lucian Iancovici resigns from board and committees - Investing.com
Ceribell, Inc. Announces Board Resignation - TradingView — Track All Markets
CeriBell, Inc. Announces Resignation of Lucian Iancovici as Chair of the Nominating and Corporate Governance Committee and as Member of the Compensation Committee, Effective as of December 31, 2025 - marketscreener.com
CeriBell stock climbs after FDA Breakthrough Device Designation - Investing.com
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Ceribell’s CFO Blumberg sells $756k in shares By Investing.com - Investing.com India
Ceribell Inc (CBLL) 재무 분석
Ceribell Inc (CBLL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Ceribell Inc 주식 (CBLL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Foehr David | Senior VP, Finance and PAO |
Jan 05 '26 |
Option Exercise |
4.70 |
5,556 |
26,113 |
22,303 |
| Foehr David | Senior VP, Finance and PAO |
Jan 05 '26 |
Sale |
22.60 |
5,556 |
125,566 |
18,900 |
| Chao Xingjuan | President and CEO |
Jan 05 '26 |
Option Exercise |
4.70 |
25,000 |
117,500 |
764,802 |
| Chao Xingjuan | President and CEO |
Jan 05 '26 |
Sale |
21.27 |
79,000 |
1,680,048 |
741,248 |
| Woo Raymond | Chief Technology Officer |
Jan 02 '26 |
Option Exercise |
4.37 |
11,112 |
48,605 |
173,932 |
| Woo Raymond | Chief Technology Officer |
Jan 02 '26 |
Sale |
21.18 |
11,112 |
235,382 |
167,317 |
| ROBERTSON REBECCA B | Director |
Jan 02 '26 |
Option Exercise |
2.24 |
2,500 |
5,600 |
22,076 |
| ROBERTSON REBECCA B | Director |
Jan 02 '26 |
Sale |
21.89 |
2,500 |
54,725 |
19,576 |
0.42%
1.96%
자본화:
|
볼륨(24시간):